TSHA
NASDAQStockTaysha Gene Therapies, Inc.
$4.50-0.10 (-2.28%)
52-Week Range
$1.13
$5.91
Key Stats
Market Cap
1.2B
P/E Ratio
—
Dividend Yield
—
Beta
1.08
Volume
3.3M
Avg Volume
2.5M
Performance
1M
+1.32%
3M
-19.97%
6M
+62.32%
YTD
-12.19%
1Y
+157.54%
3Y
+484.28%
5Y
-82.06%
Price Chart
ETF Exposure
TSHA is held by 92 ETFs
| ETF | Fund Name | Weight |
|---|---|---|
| WSML.L | iShares MSCI World Small Cap UCITS ETF | 0.01% |
| WSML | iShares MSCI World Small-Cap ETF | 0.01% |
| HDG | ProShares - Hedge Replication ETF | 0.01% |
| WDSC.L | State Street SPDR MSCI World Small Cap UCITS ETF (Acc) | 0.01% |
| WOSC.L | State Street SPDR MSCI World Small Cap UCITS ETF (Acc) | 0.01% |
| ZPRS.DE | State Street SPDR MSCI World Small Cap UCITS ETF (Acc) | 0.01% |
| ONEQ | FIDELITY NASDAQ COMPOSITE INDEX ETF | 0.00% |
| DFAS | Dimensional - US Small Cap ETF | 0.00% |
| ITOT | iShares Core S&P Total U.S. Stock Market ETF | 0.00% |
| IWV | iShares Russell 3000 ETF | 0.00% |
| SCHB | Schwab U.S. Broad Market ETF | 0.00% |
| USFM.L | UBS MSCI USA Select Factor Mix UCITS ETF USD dis | 0.00% |
| VTHR | Vanguard Russell 3000 ETF | 0.00% |
| ZPRV.DE | State Street SPDR MSCI USA Small Cap Value Weighted UCITS ETF | 0.00% |
| DCOR | Dimensional - US Core Equity 1 ETF | 0.00% |
| ITDF | iShares LifePath Target Date 2050 ETF | 0.00% |
| ITDG | iShares LifePath Target Date 2055 ETF | 0.00% |
| ITDH | iShares LifePath Target Date 2060 ETF | 0.00% |
| ITDI | iShares LifePath Target Date 2065 ETF | 0.00% |
| ITDJ | iShares LifePath Target Date 2070 ETF | 0.00% |
| VEQT.TO | Vanguard All-Equity ETF Portfolio | 0.00% |
| VTI | Vanguard Total Stock Market ETF | 0.00% |
| VUN.TO | Vanguard U.S. Total Market Index ETF | 0.00% |
| VUS.TO | Vanguard U.S. Total Market Index ETF (CAD-hedged) | 0.00% |
| XEQT.TO | iShares Core Equity ETF Portfolio | 0.00% |
| XUU.TO | iShares Core S&P U.S. Total Market Index ETF | 0.00% |
| DFAC | Dimensional - US Core Equity 2 ETF | 0.00% |
| DFAU | Dimensional - US Core Equity Market ETF | 0.00% |
| DFUS | Dimensional - US Equity Market ETF | 0.00% |
| IMID.L | State Street SPDR MSCI All Country World Investable Market UCITS ETF (Acc) | 0.00% |
| ITDB | iShares LifePath Target Date 2030 ETF | 0.00% |
| ITDC | iShares LifePath Target Date 2035 ETF | 0.00% |
| ITDD | iShares LifePath Target Date 2040 ETF | 0.00% |
| ITDE | iShares LifePath Target Date 2045 ETF | 0.00% |
| LSLT | Pacer Salt Low truBeta US Market ETF | 0.00% |
| SLT | Pacer Salt High truBeta US Market ETF | 0.00% |
| SPYI.DE | State Street SPDR MSCI All Country World Investable Market UCITS ETF (Acc) | 0.00% |
| TRPL | Pacer Metaurus US Large Cap Dividend Multiplier 300 ETF | 0.00% |
| VCNS.TO | Vanguard Conservative ETF Portfolio | 0.00% |
| VETS | Pacer Military Times Best Employers ETF | 0.00% |
| VIRS | Pacer BioThreat Strategy ETF | 0.00% |
| VRIF.TO | Vanguard Retirement Income ETF Portfolio | 0.00% |
PreviousPage 2 of 2
About TSHA ETF Exposure
Taysha Gene Therapies, Inc. (TSHA) is held by 92 exchange-traded funds, making it one of the stocks with significant ETF exposure. With a market capitalization of 1.2B, TSHA is a widely held institutional stock. The stock currently trades at $4.50. Investors can gain exposure to TSHA through a variety of ETFs with different expense ratios, investment strategies, and portfolio weightings. The table above shows all ETFs that currently hold TSHA, sorted by portfolio weight.